Biotech Values

[mcbio]

PCYC-Btk inhibitors

Peter,

Do you know anything about PCYC's Btk inhibitors, which are being developed for RA, among other indications? (See: http://www.pharmacyclics.com/img/Btk_Executive_Summary_July_2009.pdf ) They had an interesting presentation at one of the conferences previously where they were trying to convey the point that targeting the Btk pathway may have the potential for less side effects than going after the Syk pathway, as RIGL is doing.

PCYC's Btk inhibitor for RA hasn't even entered clinical trials yet, and they would owe royalties to CRA on any sales, but I am keeping an eye on PCYC given the tiny market cap.